Urethral Stricture Companies | Market Research Future

Top Industry Leaders in the Urethral Stricture Market

Urethral Strictures Key Companies *Disclaimer: List of key companies in no particular orderLatest Urethral Companies Update

Sptember 2023: Laborie Medical Technologies Inc. further expanded its portfolio through a series of recent transactions, as seen by its latest agreement to purchase Urotronic Inc. The acquisition is valued at $255 million in upfront cash, with an additional $345 million to be paid based on the achievement of certain commercial and reimbursement objectives. Laborie had previously acquired a minority stake in the maker of the Optilume drug-coated balloon technology, which is utilized for the treatment of urethral strictures and benign prostatic hyperplasia (BPH).

February 2023: scPharmaceuticals Inc. (Nasdaq: SCPH) has recently made an announcement regarding the launch and commercial availability of FUROSCIX®, a unique formulation of furosemide that is administered through an on-body infusor. This product is intended for the outpatient treatment of congestion caused by fluid overload in adult patients who have New York Heart Association (NYHA) Class II and Class III chronic heart failure. The company's primary focus is on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs. The administration of FUROSCIX is contraindicated in emergency conditions and in individuals presenting with acute pulmonary edema. The administered dosage of the FUROSCIX Infusor is limited to 80 milligrams. Acute urinary retention can be induced in individuals experiencing significant symptoms of urinary retention, which may arise from bladder emptying issues, prostatic hyperplasia, or urethral constriction, as a result of furosemide treatment. This occurrence is attributed to the heightened production and retention of urine.

List of Urethral Key companies in the market